These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
250 related items for PubMed ID: 15509675
1. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. Koss K, Harrison RF, Gregory J, Darnton SJ, Anderson MR, Jankowski JA. J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675 [Abstract] [Full Text] [Related]
2. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV. Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754 [Abstract] [Full Text] [Related]
3. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study. Beales IL, Ogunwobi O, Cameron E, El-Amin K, Mutungi G, Wilkinson M. BMC Cancer; 2007 Jun 08; 7():97. PubMed ID: 17559672 [Abstract] [Full Text] [Related]
4. Aurora kinase A in Barrett's carcinogenesis. Rugge M, Fassan M, Zaninotto G, Pizzi M, Giacomelli L, Battaglia G, Rizzetto C, Parente P, Ancona E. Hum Pathol; 2010 Oct 08; 41(10):1380-6. PubMed ID: 20656315 [Abstract] [Full Text] [Related]
5. Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma. Brundler MA, Harrison JA, de Saussure B, de Perrot M, Pepper MS. J Clin Pathol; 2006 Feb 08; 59(2):191-5. PubMed ID: 16443737 [Abstract] [Full Text] [Related]
6. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Am J Gastroenterol; 2001 Apr 08; 96(4):990-6. PubMed ID: 11316217 [Abstract] [Full Text] [Related]
7. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Jankowski JA, Anderson M. Aliment Pharmacol Ther; 2004 Oct 08; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468 [Abstract] [Full Text] [Related]
8. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Aliment Pharmacol Ther; 2008 Feb 15; 27(4):321-6. PubMed ID: 18047565 [Abstract] [Full Text] [Related]
9. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence]. Mokrowiecka A, Wierzchniewska-Ławska A, Smolarz B, Romanowicz-Makowska H, Malecka-Panas E. Pol Merkur Lekarski; 2009 May 15; 26(155):385-9. PubMed ID: 19606680 [Abstract] [Full Text] [Related]
10. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. Whittles CE, Biddlestone LR, Burton A, Barr H, Jankowski JA, Warner PJ, Shepherd NA. J Pathol; 1999 Apr 15; 187(5):535-40. PubMed ID: 10398118 [Abstract] [Full Text] [Related]
11. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus. Fortun PJ, Anagnostopoulos GK, Kaye P, James M, Foley S, Samuel S, Shonde A, Badreldin R, Campbell E, Hawkey CJ, Ragunath K. Aliment Pharmacol Ther; 2006 Mar 15; 23(6):735-42. PubMed ID: 16556175 [Abstract] [Full Text] [Related]
12. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Helm J, Enkemann SA, Coppola D, Barthel JS, Kelley ST, Yeatman TJ. Clin Cancer Res; 2005 Apr 01; 11(7):2478-85. PubMed ID: 15814623 [Abstract] [Full Text] [Related]
13. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK. Cancer Epidemiol Biomarkers Prev; 2008 Jun 01; 17(6):1380-5. PubMed ID: 18559552 [Abstract] [Full Text] [Related]
14. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer. Ling FC, Baldus SE, Khochfar J, Xi H, Neiss S, Brabender J, Metzger R, Drebber U, Dienes HP, Bollschweiler E, Hoelscher AH, Schneider PM. Histopathology; 2007 Jan 01; 50(2):203-9. PubMed ID: 17222248 [Abstract] [Full Text] [Related]
15. Cancer risk in Barrett's oesophagus. Dias Pereira A, Suspiro A, Chaves P. Eur J Gastroenterol Hepatol; 2007 Nov 01; 19(11):915-8. PubMed ID: 18049157 [Abstract] [Full Text] [Related]
17. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma. Sonoda R, Naomoto Y, Shirakawa Y, Fujiwara Y, Yamatsuji T, Noma K, Tanabe S, Takaoka M, Gunduz M, Tsujigiwa H, Nagatsuka H, Ohara N, Yoshino T, Takubo K, Vieth M, Tanaka N. Histopathology; 2010 Jul 01; 57(1):90-100. PubMed ID: 20653782 [Abstract] [Full Text] [Related]
18. Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Cameron AJ, Souto EO, Smyrk TC. Am J Gastroenterol; 2002 Jun 01; 97(6):1375-80. PubMed ID: 12094853 [Abstract] [Full Text] [Related]
19. The molecular biology of esophageal adenocarcinoma. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. J Surg Oncol; 2005 Dec 01; 92(3):169-90. PubMed ID: 16299787 [Abstract] [Full Text] [Related]
20. Barrett's oesophagus: the new endoscopic modalities have a future. Deviere J. Gut; 2005 Mar 01; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006 [Abstract] [Full Text] [Related] Page: [Next] [New Search]